​

Emergent BioSolutions (EBS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EBS Stock Forecast

Emergent BioSolutions (EBS) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 49.44% increase from the last price of $8.03.

- $3 $6 $9 $12 $15 High: $12 Avg: $12 Low: $12 Last Closed Price: $8.03

EBS Stock Rating

Emergent BioSolutions stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (73.33%), 3 Hold (20.00%), 1 Sell (6.67%), and 0 Strong Sell (0.00%).

Buy
Total 15 1 3 11 0 Strong Sell Sell Hold Buy Strong Buy

EBS Price Target Upside V Benchmarks

TypeNameUpside
StockEmergent BioSolutions49.44%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks22.64%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$12.00$12.00
Last Closing Price$8.03$8.03$8.03
Upside/Downside-49.44%49.44%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-2---2
Mar, 26-2---2
Feb, 26-2---2
Jan, 26-2---2
Dec, 25-2---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 09, 2026H.C. Wainwright$12.00$8.3543.71%49.44%
May 04, 2022Wells Fargo$38.00$33.0614.94%373.23%
Apr 29, 2022Chardan Capital$65.00$33.9891.29%709.46%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 30, 2024H.C. WainwrightBuyinitialise
Aug 22, 2024Rodman & RenshawBuyinitialise
Aug 16, 2024Benchmark Co.UnderperformUnderperformhold
Jun 24, 2024Benchmark Co.UnderperformUnderperformhold
Jun 20, 2024BenchmarkBuyBuyhold
Mar 07, 2024BenchmarkPositiveBuyupgrade
Apr 10, 2023BenchmarkHoldPositiveupgrade
Nov 10, 2022BenchmarkHolddowngrade
Apr 29, 2022Chardan CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-10 $-5 $0 $5 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.10$-4.47$-14.85$-3.60$0.98---
Avg Forecast$5.89$-1.90$-4.84$-1.64$1.29$1.27$1.11$1.31
High Forecast$5.91$-1.89$-4.63$-1.57$1.34$1.33$1.16$1.37
Low Forecast$5.86$-1.91$-5.05$-1.71$1.23$1.22$1.06$1.25
Surprise %-30.39%135.26%206.82%119.51%-24.03%---

Revenue Forecast

$500M $800M $1B $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.77B$1.12B$1.05B$1.04B$742.90M---
Avg Forecast$1.74B$1.09B$1.07B$1.10B$1.11B$1.05B$1.16B$1.22B
High Forecast$1.74B$1.09B$1.10B$1.12B$1.15B$1.07B$1.20B$1.26B
Low Forecast$1.73B$1.08B$1.03B$1.09B$1.07B$1.03B$1.13B$1.18B
Surprise %2.02%2.78%-1.65%-4.99%-33.09%---

Net Income Forecast

$-2B $-2B $-1B $-500M $0 $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$219.50M$-211.60M$-760.50M$-190.60M$52.60M---
Avg Forecast$166.73M$-102.72M$-760.50M$-83.80M$65.79M$65.05M$56.83M$67.07M
High Forecast$225.71M$-3.37M$115.75M$-80.16M$68.65M$67.88M$59.30M$69.98M
Low Forecast$107.76M$-202.07M$-1.64B$-87.44M$62.94M$62.23M$54.36M$64.16M
Surprise %31.65%105.99%-127.45%-20.05%---

EBS Forecast FAQ

Is Emergent BioSolutions stock a buy?

Emergent BioSolutions stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Emergent BioSolutions is a favorable investment for most analysts.

What is Emergent BioSolutions's price target?

Emergent BioSolutions's price target, set by 15 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 49.44% change from the previous closing price of $8.03.

How does Emergent BioSolutions stock forecast compare to its benchmarks?

Emergent BioSolutions's stock forecast shows a 49.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (22.64%).

What is the breakdown of analyst ratings for Emergent BioSolutions over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Emergent BioSolutions’s EPS forecast?

Emergent BioSolutions's average annual EPS forecast for its fiscal year ending in December 2026 is $1.27, marking a 29.59% increase from the reported $0.98 in 2025. Estimates for the following years are $1.11 in 2027, and $1.31 in 2028.

What is Emergent BioSolutions’s revenue forecast?

Emergent BioSolutions's average annual revenue forecast for its fiscal year ending in December 2026 is $1.05B, reflecting a 41.84% increase from the reported $742.9M in 2025. The forecast for 2027 is $1.16B, and $1.22B for 2028.

What is Emergent BioSolutions’s net income forecast?

Emergent BioSolutions's net income forecast for the fiscal year ending in December 2026 stands at $65.05M, representing an 23.67% increase from the reported $52.6M in 2025. Projections indicate $56.83M in 2027, and $67.07M in 2028.